|RAS001-C01||High-bind Plate||1 plate|
|RAS008-C02||SARS-CoV-2 Nucleocapsid Protein||30 μg|
|RAS008-C03||Anti-SARS-CoV-2 Nucleocapsid Antibody (Control, IgG)||10 μg|
|RAS001-C04||HRP-Anti-Human IgG||10 μg|
|RAS001-C05||Blocking / Dilution Buffer||60 mL|
Nucleocapsid (N) protein is the most abundant protein found in coronavirus. CoV N protein is a highly immunogenic phosphoprotein important for viral genome replication and modulation of cell signaling pathways. It was first identified by a research team while they were screening for ADP-ribosylated proteins during coronavirus (CoV) infection (Grunewald M. E., et al. 2017, Virology; 517: 62-68). The array of diverse functional activities accommodated in N protein makes it more than a structural protein but also an interesting target in the development of antiviral therapeutics. Because of the conservation of N protein sequence and its strong immunogenicity, N protein of coronavirus is chosen as a diagnostic tool.
This kit is developed for serologic test for IgG titer of Anti-SARS-CoV-2 Nucleocapsid Antibody in serum/plasma in vitro.
It is for research use only.
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Upon receipt, please store the lyophilized products at -20℃. After reconstitution, the stock solution should be kept at -70℃.
It is recommended not to freeze thaw more than 3 times.
This product is stable under storage conditions: 12 months in sealed state; Used within 3 months after opening.
This assay kit employs a standard indirect-ELISA format, providing a rapid detection of Anti-SARS-CoV-2 Nucleocapsid Antibody, human IgG in serum by SARS-CoV-2 Nucleocapsid Protein. The kit consists of High-bind Plate, Nucleocapsid Protein, an Anti-SARS-CoV-2 Nucleocapsid Antibody, an HRP-Anti-Human IgG secondary antibody and Blocking/Dilution buffer.
Your experiment will include 6 simple steps:
a) Coat the plate with Nucleocapsid Protein.
b) Wash the plate with universal ELISA buffer and block the plate with the blocking buffer.
c) Add your sample to the plate, take the Anti-SARS-CoV-2 Nucleocapsid Antibody as Control sample. The samples and Control sample are diluted by Blocking / Dilution Buffer.
d) Add a diluted Secondary antibody HRP-Anti-Human IgG to the plate. The Secondary antibody is diluted by Blocking / Dilution Buffer.
e) Wash the plate and add TMB or other colorimetric HRP substrate.
f) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculate as the absorbance at 450 nm minus the absorbance at 650 nm to remove background prior to statistical analysis. The OD Value reflects the amount of antibody bound.
Detection of Monoclonal Anti-SARS-CoV-2 Antibody, Human IgG1 titer by Indirect-ELISA Assay.
Immobilized SARS-CoV-2 Nucleocapsid Protein at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Nucleocapsid Antibody (Control, IgG) in 1:50 human serum. Detection was performed using HRP-Conjugated Anti-human IgG antibody with sensitivity of 6ng/mL (QC tested).